Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours
Congratulations to Kaitlin and Yordanos who just had their co-first author review published inCancers as part of a special edition on Treating the Cancer Matrix: Progress in the Identification of Potential Therapeutic Targets. Also a shout out to Rhiannon for her amazing illustrator skills and creating some beautiful figures. And finally to Jess, who as co-senior author played an instrumental role in bringing everything together.
The Role of the ECM in Lung Cancer Dormancy and Outgrowth
We are pleased to report that our recent in depth review on the role of the extracellular matrix (ECM) in Lung cancer, both in primary and metastatic settings has just been published as part of a special edition on ‘Revisiting Seed and Soil: A New Approach to Target Hibernating Dormant Tumor Cells‘ in Frontiers in Oncology: Molecular and Cellular Oncology.
It’s with great excitement that we welcome our newest PostDoc to the team, Amelia Parker.
Amelia joins us having returned from a PostDoctoral position at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in the USA. Prior to this she completed her Ph.D. in the laboratories of Professor Maria Kavallaris and A/Prof Joshua McCarroll at The Children’s Cancer Institute (CCI) in Sydney.
As a biomedical engineer and cancer biologist, Amelia is interested in the importance of the tumour microenvironment, and in particular the extracellular matrix (ECM) in driving tumour progression.
Amelia’s work will focus on the importance of the ECM in Lung Cancer onset and progression.
LOXL1 Is Regulated by Integrin α11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity
Our lab has contributed to a recent paper by Zeltz and colleagues looking at the interplay between Lysyl Oxidase Like 1 (LOXL1) and Integrin α11 in Non-Small Cell Lung Cancer (NSCLC). The work was published in the Open-Access journal Cancers.